{
    "clinical_study": {
        "@rank": "147873", 
        "arm_group": [
            {
                "arm_group_label": "Ascorbic Acid + Sorafenib", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate\nDosage:\nVitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
            }, 
            {
                "arm_group_label": "Sorafenib alone", 
                "arm_group_type": "Other", 
                "description": "Sorafenib: taken daily (oral)"
            }
        ], 
        "brief_summary": {
            "textblock": "This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment\n      with sorafenib versus treatment with sorafenib alone in subjects with metastatic\n      hepatocellular carcinoma. The phase I aspect will assess the safety and efficacy of the\n      concurrent treatments and the phase II aspect will utilize CT (computer-tomography) scans to\n      assess overall tumor response rate and evaluate disease progression"
        }, 
        "brief_title": "A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Hepatocellular Carcinoma", 
            "Advanced Liver Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "Intravenous Ascorbic Acid (Vitamin C) is a widely used alternative cancer treatment. This\n      trial will study an intravenous Vitamin C treatment for persons with liver cancer that has\n      spread, who are also receiving Sorafenib (a standard cancer drug), to see whether the\n      combination of Vitamin C and Sorafenib is safe and well tolerated. Phase I will involve 6\n      persons who will receive the Vitamin C for 8 weeks to more specifically assess the safety of\n      getting Vitamin C in combination with Sorafenib. Phase II will be randomized to receive\n      either Vitamin C plus Sorafenib or Sorafenib alone for 16 weeks. If Vitamin C has a\n      beneficial effect on tumour cells, patients may experience a regression of tumor or tumor\n      markers. Additional benefits include scans at no charge to the patient."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years\n\n          -  Metastatic hepatocellular carcinoma\n\n          -  G6PD (glucose-6-phosphate dehydrogenase) status > lower limit of normal\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n\n          -  Laboratory at baseline evaluation for inclusion in the study: creatinine      \u22641.5X\n             upper limit (if the creatinine is elevated, but \u22641.5X the ULN, a 24 hour creatinine\n             clearance will be obtained); transaminase (AST/ALT) \u22642.0X upper limit of normal;\n             bilirubin levels \u2265 2 mg/dL; ANC \u22651,500/mm3; Hemoglobin > 8g/dL; platelet \u2265\n             100,000/mm3\n\n          -  Women of childbearing potential will confirm a negative pregnancy test and     must\n             practice effective contraception during the study.\n\n          -  Willing and able to provide informed consent and participate in the study procedures.\n\n        Exclusion Criteria:\n\n          -  Patients with evidence of a significant current psychiatric disorder that would\n             prevent completion of the study as determined by the PI will not be allowed to\n             participate.\n\n          -  Co-morbid medical condition that would affect survival or tolerance as determined by\n             the PI. This includes patients who have not fully recovered from toxicities\n             associated with prior therapy. It also includes subjects who, as determined by the\n             PI, are at risk of experiencing fluid overload (i.e., congestive heart failure).\n\n          -  Patients who currently abuse alcohol or drugs.\n\n          -  Patients with known glomerular filtration rate of <60ml/min or with nephrotic range\n             proteinuria.\n\n          -  Pregnant or lactating women\n\n          -  Enrollment in active clinical trial/ experimental therapy or IND study within the\n             prior 30 days.\n\n          -  Contraindication for CT or PET/CT as per the PI."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754987", 
            "org_study_id": "12D.424"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ascorbic Acid + Sorafenib", 
                "intervention_name": "Ascorbic Acid + Sorafenib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vitamin C", 
                    "Ascorbate"
                ]
            }, 
            {
                "arm_group_label": "Sorafenib alone", 
                "intervention_name": "Sorafenib alone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sorafenib", 
                "Antineoplastic Agents", 
                "Antineoplastic Agents, Phytogenic", 
                "Ascorbic Acid", 
                "Vitamins", 
                "Radiation-Sensitizing Agents", 
                "Molecular Mechanisms of Pharmacological Action", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Vitamins", 
            "Malignant Tumor, Tumour", 
            "Integrative Medicine", 
            "Complementary Medicine", 
            "Alternative Medicine Antioxidants", 
            "Molecular Mechanisms of Pharmacological Action", 
            "Pharmacologic Actions", 
            "Protective Agents", 
            "Physiological Effects of Drugs", 
            "Micronutrients", 
            "Growth Substances", 
            "Antineoplastic Agents, Phytogenic", 
            "Antineoplastic Agents", 
            "Therapeutic Uses", 
            "Radiation-Sensitizing Agents", 
            "Liver Cancer"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "daniel.monti@jefferson.edu", 
                "last_name": "Daniel A Monti, MD", 
                "phone": "215-955-4410"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19107"
                }, 
                "name": "Thomas Jefferson University"
            }, 
            "investigator": [
                {
                    "last_name": "Daniel A Monti, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Susan J Littman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Edith P Mitchell, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nancy Lewis, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Madhavan Pillai, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anthony J Bazzan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andrew B Newberg, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma", 
        "overall_contact": {
            "email": "michael.matthews@jefferson.edu", 
            "last_name": "Michael Matthews", 
            "phone": "215-503-7329"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary aim is to assess whether or not (IV) Ascorbic Acid (AA) with sorafenib therapy is relatively safe and well-tolerated according to Common Terminology Criteria for Adverse Events (CTCAE)v4.0", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "16 weeks +/- 2 weeks"
        }, 
        "reference": {
            "PMID": "22272248", 
            "citation": "Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. Epub 2012 Jan 17."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754987"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To utilize CT or PET/CT scans to assess overall tumor response rate (complete and partial response) and evaluate disease progression in subjects with advanced metastatic hepatocellular cancer treated with the combination of ascorbic acid and sorafenib versus sorafenib alone.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "16 weeks +/- 2 weeks"
            }, 
            {
                "description": "1) To evaluate quality of life using Functional Assessment of Cancer Therapy-General (FACT-G) quality assessment instrument. The FACT-G questionnaire as well as the Patient Reported Outcomes Measurement Information System (PROMIS-29) will be used to assess quality-of-life longitudinally. Quality-of-life scores obtained from the FACT-G and PROMIS-29 will be summarized at multiple time points using means and standard deviations.", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "16 weeks +/- 2 weeks"
            }, 
            {
                "description": "To evaluate duration of tumor response and progression-free survival", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "15 weeks+"
            }
        ], 
        "source": "Thomas Jefferson University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Thomas Jefferson University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}